C21 - Efficacy and Safety of Peptide Receptor Radionuclide Therapy in Lung Neuroendocrine Tumors: A Multicentre Study

Published in 2020 Listed under Clinical-PRRT-Nuclear

A. Iravani, L. Zidan, K. Oleinikov, S. Ben-Haim, D. Gross, A. Meirovitz, O. Maimon, T. Akhurst, M. Michael, R. Hicks, S. Grozinsky-Glasberg, G. Kong

ABSTRACT ID: 15

C22 - Patient Travel Concerns After Treatment with Peptide Receptor Radionuclide Therapy (PRRT)

Published in 2020 Listed under Clinical-PRRT-Nuclear

A. Kendi, T. Halfdanarson, B. Naraev, D. Mercer, J. Underwood, J. Mailman

ABSTRACT ID: 36

C24 - A Clinical Score(CS) for Well- Differentiated Neuroendocrine Tumor(WD-NET) Patients(Pts) Undergoing Peptide Receptor Radionuclide Therapy(PRRT)

Published in 2020 Listed under Clinical-PRRT-Nuclear

S. Das, L. Du, A. Schad, S. Jain, A. Jessop, C. Shah, D. Eisner, D. Cardin, K. Ciombor, L. Goff, M. Bradshaw, D. Delbeke, M. Sandler, J. Berlin

ABSTRACT ID: 44

C26 - Safety of 177Lu DOTATATE in Patients with Advanced Neuroendocrine Tumors: Data from a US Expanded Access Program

Published in 2020 Listed under Clinical-PRRT-Nuclear

M. Allen-Auerbach, E. Wolin, V. Nassiri, P. Broberg, G. El-Haddad

ABSTRACT ID: 118

C27 - Re-Treatment with 177Lu-DOTATATE in Patients With Neuroendocrine Tumors: Multicenter Real-World Experience

Published in 2020 Listed under Clinical-PRRT-Nuclear

S. Navalkissoor, M. Essler, M. Caplin, W. Van Der Zwan, M. Wicharz, W. De Herder, P. Broberg, E. Krenning

ABSTRACT ID: 119

C28 - Supportive Management during PRRT for Symptomatic Pheochromocytomas or Paragangliomas

Published in 2020 Listed under Clinical-PRRT-Nuclear

E. Tsang, G. Funk, J. Leung, G. Kalish, H. Kennecke

ABSTRACT ID: 134

C30 - 64Cu-DOTATATE PET in Neuroendocrine Tumor Patients: What We Learned From the First 1,200 Patients

Published in 2020 Listed under Clinical-PRRT-Nuclear

A. Kjaer, E. Carlsen, M. Loft, C. Johnbeck, T. Binderup, S. Langer, B. Federspiel, U. Knigge

ABSTRACT ID: 147

C31 - PRRT Neuroendocrine Tumor Response Monitored Using Circulating Transcript Analysis: The NETest

Published in 2020 Listed under Clinical-PRRT-Nuclear

L. Bodei, M. Kidd, A. Singh, W. Van Der Zwan, S. Severi, I. Drozdov, A. Malczewska, G. Paganelli, E. Krenning, I. Modlin

ABSTRACT ID: 160

C32 - Dynamic Contrast-Enhanced CT to Evaluate Response in Neuroendocrine Liver Metastases Treated with Everolimus and Radiation

Published in 2020 Listed under Clinical-PRRT-Nuclear

J. Hudson, S. Singh, V. Rodriguez-Freixinos, D. Chan, J. Hallet, C. Law, S. Myrehaug

ABSTRACT ID: 165

C33 - Association Between Surveillance Imaging and Survival Outcomes in Small Bowel Neuroendocrine Tumors

Published in 2020 Listed under Clinical-PRRT-Nuclear

A. Watanabe, L. Yip, G. McKendry, J. Loree, H. Stuart

ABSTRACT ID: 167

C35 - Real-World Analysis of Safety and Tolerance of Repeat Peptide Receptor Radionuclide Therapy

Published in 2020 Listed under Clinical-PRRT-Nuclear

J. Chau, H. Bakeri, N. Yu, Y. Menda, J. Dillon, C. Chandrasekharan

ABSTRACT ID: 192

C36 - 212Pb-AlphaMedixTM Targeted Alpha Therapy (TAT): A Potential Breakthrough in Treatment of Metastatic SSTR Expressing NET

Published in 2020 Listed under Clinical-PRRT-Nuclear

E. Delpassand, I. Tworowska, J. Torgue, J. Hurt, R. Nuñez, R. Esfandiari

ABSTRACT ID: 193

C39 - Hematotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) – A Single Institution Experience

Published in 2020 Listed under Clinical-PRRT-Nuclear

H. Duan, V. Ferri, P. Kunz, G. Davidzon, F. Moradi, J. Nguyen, B. Franc, A. Iagaru, C. Aparici Mari

ABSTRACT ID: 199

C40 - Renal and Hepatotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) – A Single Institution Experience

Published in 2020 Listed under Clinical-PRRT-Nuclear

H. Duan, V. Ferri, P. Kunz, G. Davidzon, J. Nguyen, F. Moradi, B. Franc, A. Iagaru, C. Aparici Mari

ABSTRACT ID: 201